Neurobiology of Aging
Volume 29, Issue 7 , Pages 961-968 , July 2008

Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease

  • A.H. Simonsen

      Affiliations

    • Biomarker Discovery Center® Facility, Ciphergen Biosystems Inc., Copenhagen, Denmark
    • Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author at: Ciphergen Biosystems, Symbion Suite 253, Fruebjergvej 3, 2100 Copenhagen O, Denmark. Tel.: +45 3917 9748; fax: +45 3917 9742.
    • ,
  • J. McGuire

      Affiliations

    • Biomarker Discovery Center® Facility, Ciphergen Biosystems Inc., Copenhagen, Denmark
    • ,
  • V.N. Podust

      Affiliations

    • Biomarker Discovery Center® Facility, Ciphergen Biosystems Inc., Fremont, CA, USA
    • ,
  • H. Davies

      Affiliations

    • Biomarker Discovery Center® Facility, Ciphergen Biosystems Inc., Copenhagen, Denmark
    • ,
  • L. Minthon

      Affiliations

    • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
    • ,
  • I. Skoog

      Affiliations

    • Department of Neuroscience and Physiology, Sahlgren's University Hospital, Sweden
    • ,
  • N. Andreasen

      Affiliations

    • Department of Geriatric Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden
    • ,
  • A. Wallin

      Affiliations

    • Department of Geriatric Medicine, Karolinska Institute, Karolinska University Hospital, Huddinge, Sweden
    • ,
  • G. Waldemar

      Affiliations

    • Memory Disorders Research Group, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark
    • ,
  • K. Blennow

      Affiliations

    • Department of Clinical Neuroscience, Sahlgrenska University Hospital, Mölndal, Sweden

Received 15 September 2006 ,Revised 17 January 2007 ,Accepted 21 January 2007.

References 

  1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 2000;21:383–421
  2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605–613
  3. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995;26:231–245
  4. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics. 2003;3:1486–1494
  5. Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731–1735
  6. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38:1688–1693
  7. Frank, R.A., Galasko, D., Hampel, H., Hardy, J., de Leon, M., Mehta, P., Rogers, J., Siemers, E., Trojanowski, J.Q., Biological markers for therapeutic trials in Alzheimer's disease. In: Proceedings of the Biological Markers Working Group; NIA Initiative on Neuroimaging in Alzheimer's Disease, Neurobiol. Aging, vol. 24, 2003, pp. 521–536.
  8. Friedland RP. Alzheimer's disease: clinical features and differential diagnosis. Neurology. 1993;43:S45–S51
  9. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. J. Neural. Transm. 1998;54(Suppl.):77–95
  10. Kosunen O, Soininen H, Paljarvi L, Heinonen O, Talasniemi S, Riekkinen PJ. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. 1996;91:185–193
  11. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry. 2004;55:524–530
  12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  13. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid SA, et al. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 2005;196:273–281
  14. Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, et al. Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?. Ann. Neurol. 2005;58:139–142
  15. Simonsen, A.H., Hansson, S.F., Ruetschi, U., McGuire, J., Podust, V.N., Davies, H.A., Mehta, S.P., Waldemar, G., Zetterberg, H., Andreasen, N., Wallin, A., Blennow, K., Aβ1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dementia Geriatric Cogn. Disord., in press.
  16. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J. Neurol. Sci. 1970;11:205–242
  17. Vanderstichele H, Van KE, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245–258

PII: S0197-4580(07)00018-8

doi: 10.1016/j.neurobiolaging.2007.01.011

Neurobiology of Aging
Volume 29, Issue 7 , Pages 961-968 , July 2008

Article Tools

* Image Usage & Resolution